Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL140298 | 0.86 | LMNA (0.55) | LMNA | |
| SCHEMBL2698061 | 0.84 | LMNA (0.63) | LMNA | |
| Cyclohexanone SCHEMBL3835265 | 0.81 | LMNA (0.48) | LMNA | |
| Ethylene SCHEMBL4424062 | 0.79 | LMNA (0.50) | LMNA | |
| Ethylene SCHEMBL9049781 | 0.78 | LMNA (0.44) | LMNA | |
| Ethylene SCHEMBL8915548 | 0.76 | LMNA (0.43) | LMNA | |
| Ethylene SCHEMBL3238455 | 0.76 | LMNA (0.43) | LMNA | |
| Cyclohexanone SCHEMBL6517734 | 0.76 | LMNA (0.52) | LMNA | |
| Ethylene SCHEMBL2909659 | 0.75 | LMNA (0.50) | LMNA | |
| Ethylene SCHEMBL383298 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082761-A1 | DUAL-TARGETED RNA POLYMERASE INHIBITORS: CONJUGATES OF BENZOXAZINO- AND SPIRO-RIFAMYCINS WITH N ALPHA-AROYL-N-ARYL-PHENYLALANINAMIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2024213125-A1 | BRM SELECTIVE DEGRADATION AGENT AND USE THEREOF | 南京再明医药有限公司 | 2024-10-17 | — | — | WO | disclosed |
| EP-4387618-A1 | DUAL-TARGETED RNA POLYMERASE INHIBITORS: CONJUGATES OF BENZOXAZINO- AND SPIRO-RIFAMYCINS WITH N?-AROYL- N-ARYL-PHENYLALANINAMIDES | Rutgers, the State University of New Jersey (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11884654-B2 | Substituted anilines as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2023125944-A1 | COMPOUND CONTAINING HETEROCYCLIC RING | 正大天晴药业集团股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023023378-A1 | DUAL-TARGETED RNA POLYMERASE INHIBITORS: CONJUGATES OF BENZOXAZINO- AND SPIRO-RIFAMYCINS WITH Nα-AROYL- N-ARYL-PHENYLALANINAMIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-4129996-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20220194929-A1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2022-06-23 | — | — | US | disclosed |
| WO-2022127807-A1 | CRYSTAL FORM OF ARYL PHOSPHORUS OXIDE DERIVATIVE FREE BASE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 | 2022-06-23 | — | — | WO | disclosed |
| CN-103998429-B | Substituted phenyl amines as CCR (4) antagonist | 凯莫森特里克斯股份有限公司 | 2016-12-07 | — | — | CN | disclosed |
| US-20160317545-A1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20150141397-A1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2015-05-21 | — | — | US | disclosed |
| EP-2785692-A1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | ChemoCentryx, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8835419-B2 | Substituted anilines as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| CN-103998429-A | Substituted anilines as ccr(4) antagonists | CHEMOCENTRYX INC | 2014-08-20 | — | — | CN | disclosed |
| US-20130172315-A1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013082490-A1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| WO-2009036035-A1 | BCL-2 INHIBITORS | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-3959300-A | Novel indolobenzazepine derivatives, useful as tranquilizers | ENDO LABORATORIES, INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884654-B2 | Substituted anilines as CCR(4) antagonists | CCR4, CCR1, CCR3 | LMNA 4686/4885HTR2C 766/4885 |
| US-20220194929-A1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | LMNA 4686/4885HTR2C 766/4885 |
| US-20160317545-A1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | LMNA 4686/4885HTR2C 766/4885 |
| US-20250082761-A1 | DUAL-TARGETED RNA POLYMERASE INHIBITORS: CONJUGATES OF BENZOXAZINO- AND SPIRO-RIFAMYCINS WITH N ALPHA-AROYL-N-ARYL-PHENYLALANINAMIDES | COASY, POLR2A, POLR2H | LMNA 1343/4885HTR2C 4402/4885 |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | LMNA 4573/4885HTR2C 2532/4885 |
| US-20150141397-A1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | LMNA 4686/4885HTR2C 766/4885 |
| US-20130172315-A1 | SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | LMNA 4686/4885HTR2C 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.